Sintilimab is a domestically developed anti-PD-1 monoclonal antibody, trade name: Daboshu, which is jointly developed by Cinda Biopharmaceuticals and Eli Lilly in China. Like imported PD-1 monoclonal antibodies (O drugs, K drugs), it can specifically bind to the PD-1 molecules on the surface of T cells, thereby blocking the PD-1/PD-L1 pathway that leads to tumor immune tolerance and reactivating the lymph The anti-tumor activity of the cells achieves the purpose of treating tumors. Sintilimab is the first Chinese immunotherapy drug to be listed in the top journal “The Lancet Medicine”. In December 2018, Sintilizumab was approved to treat relapsed/refractory classic Hodgkin’s lymphoma. The international standard treatment for relapsed and refractory Hodgkin’s lymphoma is autologous hematopoietic stem cell transplantation and Bentuximab. However, due to economic constraints or the inability to purchase this drug, most patients in China cannot receive standard treatment. It should be said that the listing of Daboshu provides more choices for such patients. The clinical trial ORIENT-1, led by Professor Shi Yuankai, Department of Internal Medicine, Cancer Hospital of the Medical Academy of Medicine, showed that the drug has an effective rate of 80.4%. Regarding the indications of lung cancer, the National Medical Products Administration (NMPA) has officially accepted the application of Sintilimab combined with chemotherapy for the first-line treatment of lung cancer, including two indications for squamous cell carcinoma and non-squamous cell carcinoma. The results of the first-line clinical trial (ORIENT-11) for the treatment of advanced non-squamous non-small cell lung cancer with Sintilimab combined with Libitai and platinum-based chemotherapy at the 2020 World Lung Cancer Conference in Advanced Recurrent Non-Squamous Non-Small Cell Lung Cancer Experimental group (sintilimab+pemetrexed+platinum chemotherapy) vs. control group (placebo+pemetrexed+platinum chemotherapy), median progression-free survival (mPFS): 8.9 months vs. 5 At 0 months, the risk of progression in the combination therapy group was reduced by 52%. Objective response rate (ORR): 51.9% vs. 29.8%, and sintilimab can make the patient get remission earlier (1.51 months). The phase III study (ORIENT-12) of sintilimab combined with gemcitabine and platinum-based chemotherapy for the first-line treatment of squamous non-small cell lung cancer for advanced recurrent squamous cell carcinoma reached its primary endpoint. The experimental group was Sintilimab, gemcitabine and platinum, while the control group replaced Sintilimab with a placebo. The results of the study showed that the progression-free survival (PFS) of the experimental group (sintilimab+gemcitabine+platinum) vs. the control group (placebo+gemcitabine+platinum) was significantly prolonged, and compared with previous studies, there is nothing new The safety signal appears. In November 2019, Sintilimab was included in the national medical insurance and entered the first batch of 4+7 drug catalogs, becoming the only PD-1 antibody in the medical insurance catalog, with a price of 2843 yuan per bottle. Compared with similar domestic PD-1 monoclonal antibodies, the price is very close to the people, but the cancer type that can be reimbursed at present is relapsed/refractory Hodgkin’s lymphoma. I hope that Sintilimab will be approved for lung cancer indications as soon as possible, so that more lung cancer patients can use this civilian immunotherapy.